On-Demand Webinar

Pharmacometrics Under Pressure: The Quantitative Clinical Pharmacology Sprint

Explore how Phoenix NLME and RsNLME support early phase clinical pharmacology workflows where speed, clarity,…

CertaraMay 6, 2026

Blog

GxP Compliance in the Cloud: What IT Teams Need to Rethink

Learn how GxP validation works in modern SaaS and cloud environments, with best practices for…

CertaraMay 4, 2026

Webinar

Allometric Approach in pharmacokinetics when and how to use it

Danielle PillsburyApril 28, 2026

Blog

From Models to Impact: What QSPC 2026 Revealed About the Future of Drug Development

Explore Certara’s insights from QSPC 2026, including virtual patients, regulatory adoption, AI in QSP, and…

CertaraApril 28, 2026

Blog

ADC Dose Optimization: Applying Model-Informed Strategies in Development

Explore ADC dose optimization using model-informed strategies to balance efficacy and safety across antibody drug…

CertaraApril 22, 2026

Blog Knowledge Base

Mean Residence Time (MRT): Understanding How Long Drug Molecules Stay in the Body

JTVCdGVhbV9qdW1wX2xpc3QlNUQ= April 16, 2026 When I first began learning about pharmacokinetics (PK), I was often…

CertaraApril 16, 2026

Webinar

When pharmacokinetics meets pharmacogenomics: Genetic Insights into Fluoxetine PK for Personalized Antidepressant Therapy

CertaraApril 10, 2026

Blog

PK Parameters Explained: From Cmax to Clearance (and Why It Matters for Development Decisions)

Learn how key PK parameters such as Cmax, AUC, clearance, half life, and volume of…

CertaraApril 9, 2026

On-Demand Webinar

Final ICH M15 Guidance: Aligning MIDD with Global Regulatory Expectations

Watch this on-demand webinar to learn how the final ICH M15 guidance is shaping Model-Informed…

CertaraApril 2, 2026

Publication

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib

This study demonstrates how a model-informed, totality-of-evidence approach was used to select the optimal clinical…

Danielle PillsburyApril 2, 2026

Modeling and Simulation – PK/PD

Pharmacometrics Under Pressure: The Quantitative Clinical Pharmacology Sprint

GxP Compliance in the Cloud: What IT Teams Need to Rethink

Allometric Approach in pharmacokinetics when and how to use it

From Models to Impact: What QSPC 2026 Revealed About the Future of Drug Development

ADC Dose Optimization: Applying Model-Informed Strategies in Development

Mean Residence Time (MRT): Understanding How Long Drug Molecules Stay in the Body

When pharmacokinetics meets pharmacogenomics: Genetic Insights into Fluoxetine PK for Personalized Antidepressant Therapy

PK Parameters Explained: From Cmax to Clearance (and Why It Matters for Development Decisions)

Final ICH M15 Guidance: Aligning MIDD with Global Regulatory Expectations

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib

Newsletter sign up

Quick links

Solutions

Contact